Larimar soars as FDA removes partial clinical hold on genetic disease therapy

Larimar Therapeutics

21/05/2024 09:59

** Shares of drug developer Larimar Therapeutics  LRMR.O 
rise 18% to $8.58 premarket
    ** Co says U.S. FDA has removed the partial clinical hold
previously placed on its experimental genetic disease therapy
Nomlabofusp
    ** Nomlabofusp is being tested as a potential treatment of
Friedreich's ataxia, a rare inherited disease that causes
nervous system damage and movement problems
    ** The FDA removed the partial clinical hold after a review
of data from co's recently completed four-week mid-stage trial
    ** LRMR plans to submit a marketing application for the
therapy in 2H25
    ** Up to last close, stock up 59.8% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))